Merck's Space-Based Research Yields Promising Results for Cancer Drug Keytruda

Pharmaceutical giant Merck (MRK) saw its shares rise by approximately 1.0% to $146.39 on Thursday, driven in part by the company's foray into commercial space research. This collaboration with NASA has yielded promising results, particularly in the development of a faster subcutaneous formulation of Keytruda, a blockbuster cancer drug that generated about $8.37 billion of Merck's latest $16.61 billion quarter.

The International Space Station played host to research that better understood protein crystallization, a key aspect of drug development. Microgravity was found to produce larger and more orderly protein crystals, which can provide clearer structural information for researchers. This breakthrough has significant commercial implications, with the subcutaneous version of Keytruda contributing $463 million, or around 5.5% of total sales.

However, the regulatory landscape remains uncertain, as there is currently no purpose-built approval framework for medicines manufactured in space. The commercial stakes are already substantial, with investors willing to pay a premium, Merck trades 21.85% above its GF Value estimate of $120.14. Yet, the question remains whether future orbital breakthroughs can become commercially meaningful medicines often enough to justify the cost and complexity.